Moreover, ROR1 signaling induced by Wnt5a can promote CLL-cell survival, growth, and migration, which can be inhibited by cirmtuzumab, a mAb specific for the extracellular domain of ROR1 [10, 16]. Here, WNT5A is linked to B-cell chronic lymphocytic leukemia.